Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01113385 · ClinicalTrials.gov registry record · NA
Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome
A NA study of Focal Segmental Glomerulosclerosis and Steroid Resistant Nephrotic Syndrome, sponsored by Children's National Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT01113385 is a NA study of Focal Segmental Glomerulosclerosis and Steroid Resistant Nephrotic Syndrome that has completed, run by Children's National Research Institute. The registered enrollment target is 7 participants, below the 236-participant average among 19 other Focal Segmental Glomerulosclerosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01113385, a NA study of Focal Segmental Glomerulosclerosis and Steroid Resistant Nephrotic Syndrome, has completed, sponsored by Children's National Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
Focal Segmental Glomerulosclerosis (FSGS) is a devastating kidney disease which is difficult to treat and carries a poor prognosis, with 50% of affected children progressing to end stage renal disease (ESRD). The purpose of this study is to investigate oral galactose as a benign treatment for FSGS in children. The investigators hypothesize that galactose, a simple milk sugar thought to bind to the protein factor (FSPF) that causes FSGS thereby inactivating it and stopping it from damaging the kidney, resulting in a reduction in glomerular permeability to albumin and decrease in proteinuria in children with nephrotic syndrome secondary to FSGS.
Conditions Studied
Interventions
- DRUG D-Galactose
Study Locations (1)
District of Columbia
- Children's National Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2009-10 |
| Est. Completion | 2013-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01113385
The ClinicalTrials.gov registry entry for NCT01113385 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 236-participant average among 19 other Focal Segmental Glomerulosclerosis trials with a reported enrollment target (97% lower). The listed sponsor is Children's National Research Institute, which has 92 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Focal Segmental Glomerulosclerosis appearing as the primary indexed condition, and to 1 intervention - of which D-Galactose is the first listed.
NCT01113385 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT01113385 about?
NCT01113385 is a clinical study titled "Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome". Focal Segmental Glomerulosclerosis (FSGS) is a devastating kidney disease which is difficult to treat and carries a poor prognosis, with 50% of affected children progressing to end stage renal disease (ESRD). The purpose of this study is to investigate oral galactose as a benign treatment for FSGS i...
What is the current status of trial NCT01113385?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2009-10. Estimated completion is 2013-03.
What conditions does trial NCT01113385 study?
This clinical trial studies the following conditions: Focal Segmental Glomerulosclerosis, Steroid Resistant Nephrotic Syndrome.
What interventions are being tested in trial NCT01113385?
The interventions under investigation include: D-Galactose (DRUG).
Who is sponsoring clinical trial NCT01113385?
This trial is sponsored by Children's National Research Institute, which has 92 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01113385 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Focal Segmental Glomerulosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
RECRUITING · NA
-
NEPTUNE Match Study
RECRUITING · NA
-
taVNS for FRNS in Children
RECRUITING · NA
-
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
RECRUITING · NA
-
A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)
RECRUITING · NA
-
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
RECRUITING
Explore more on PlainTrial
Focal Segmental Glomerulosclerosis
All registered trials for this condition
Steroid Resistant Nephrotic Syndrome
All registered trials for this condition
District of Columbia
All trials with a study site in District of Columbia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.